A phase I study of tremelimumab, durvalumab, and hypofractionated radiotherapy for metastatic gynecologic cancers (040)Lilie L. Lin, Kevin Albuquerque, Ann H. Klopp et al.|Gynecologic Oncology|2023Cited by 1